• -
  • English
  • Japanese
  • Korean
表紙
市場調查報告書
商品編碼
1084116

腫瘤學生物相似藥的按全球市場(2022年∼2028年):各適應症，醫藥品分類，各給藥途徑，各終端用戶，各流通管道，各地區的市場規模調查與預測

Global Oncology Biosimilars Market Size study, By Indication, By Drug Class, By Route of Administration, By End-Users, By Distribution Channel, and Regional Forecasts 2022-2028
出版日期: | 出版商: Bizwit Research & Consulting LLP | 英文 | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球腫瘤學生物相似藥的市場規模，在2022年∼2028年的預測期間內預計以健全成長率擴大。牽引市場的主要原因，有全球癌症的盛行率增加，合理價格的生物相似藥醫藥品的需求增加，大企業最近的夥伴關係與產品的銷售等。可是，醫藥品開發、銷售相關的高成本和醫藥品開發、核準的複雜流程，阻礙預測期間的市場成長。

本報告提供全球腫瘤學生物相似藥市場調查，市場概要，市場的推動因素與阻礙因素的分析，市場機會，COVID-19影響，各市場區隔的市場分析，競爭情形，主要企業的簡介等系統性資訊。

目錄

第1章 摘要整理

第2章 全球腫瘤學生物相似藥市場:定義和範圍

第3章 全球腫瘤學生物相似藥:市場動態

  • 腫瘤學生物相似藥市場:影響分析(2020年∼2028年)

第4章 全球腫瘤學生物相似藥市場:產業分析

  • 波特的五力分析
  • PEST分析
  • 投資採用模式
  • 分析師的推薦事項與結論
  • 主要的投資機會
  • 主要的成功策略

第5章 風險評估:COVID-19影響

    • COVID-19對產業的整體影響的評估
    • COVID-19前及COVID-19後的市場情境

第6章 全球腫瘤學生物相似藥市場:各適應症

  • 市場概述
  • 成果:潛力分析
  • 市場規模的估計與預測(2018年∼2028年)
  • 子區隔分析
    • 乳癌
    • 肺癌症
    • 結腸直腸癌症
    • 子宮頸癌症
    • 血液癌症
    • 其他

第7章 全球腫瘤學生物相似藥市場:各醫藥品分類

  • 市場概述
  • 成果:潛力分析
  • 市場規模的估計與預測(2018年∼2028年)
  • 子區隔分析
    • 單株抗體
    • 顆粒細胞增生因子
    • 其他

第8章 全球腫瘤學生物相似藥市場:各給藥途徑

  • 市場概述
  • 成果:潛力分析
  • 市場規模的估計與預測(2018年∼2028年)
  • 子區隔分析
    • 靜脈內
    • 皮下
    • 其他

第9章 全球腫瘤學生物相似藥市場:各終端用戶

  • 市場概述
  • 成果:潛力分析
  • 市場規模的估計與預測(2018年∼2028年)
  • 子區隔分析
    • 醫院
    • 專門診療所
    • 居家醫療
    • 其他

第10章 全球腫瘤學生物相似藥市場:各流通管道

  • 市場概述
  • 成果:潛力分析
  • 市場規模的估計與預測(2018年∼2028年)
  • 子區隔分析
    • 醫院藥局
    • 零售藥局
    • 線上藥局
    • 其他

第11章 全球腫瘤學生物相似藥市場:地區分析

  • 地區市場概述
  • 北美
    • 美國
    • 加拿大
  • 歐洲的概述
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 其他歐洲
  • 亞太地區的概述
    • 中國
    • 印度
    • 日本
    • 澳洲
    • 韓國
    • 其他亞太地區
  • 南美的概述
    • 巴西
    • 墨西哥
  • 其他地區

第12章 競爭情形

  • 主要市場策略
  • 企業簡介
    • Pfizer Inc.(美國)
    • GlaxoSmithKline plc(英國)
    • Novartis AG(瑞士)
    • Mylan N.V.(美國)
    • Teva Pharmaceutical Industries Ltd.(以色列)
    • Sanofi(法國)
    • F. Hoffmann-La Roche Ltd.(瑞士)
    • Zydus Cadila(印度)
    • Lupin(印度)
    • Amneal Pharmaceuticals LLC.(美國)

第13章 調查流程

目錄

Global Oncology Biosimilars Market is valued approximately USD XX million in 2021 and is anticipated to grow with a healthy growth rate of more than XX % over the forecast period 2022-2028. Oncology Biosimilars can be defined as a version of a known and proven biologic drug. These drugs are made from living things such as cells, tissues, or proteins. Biosimilars are more affordable alternatives to similar other drugs. Also, biosimilar offers similar safety and toxicity profile. Growing prevalence of cancer worldwide and increasing demand for biosimilar drugs due to affordability as well as recent partnerships and product launches from leading players are key drivers for growth of Oncology Biosimilars Market. For instance, according to World Cancer Research Fund - in 2020, around 18.1 million cancer cases were reported globally. Around 9.3 million cases were in men and 8.8 million in women. Further, Breast and lung cancers were most prevalent type of cancers worldwide, contributing 12.5% and 12.2% of all cancer cases reported in 2020. Moreover, in March 2019, the United States (U.S.) Food and Drug Administration (FDA) has approved new biosimilar from Pfizer Inc. named TRAZIMERA (trastuzumab-qyyp). This new drug is a biosimilar to Herceptin (trastuzumab). This new drug is intended for the treatment of breast cancer and Esophageal cancer. Further, in March 2022, Cipla Medpro, a wholly owned subsidiary of Cipla Limited, India entered in a partnership agreement with Madrid, Spain based mAbxience. Under this partnership both the companies would work towards bringing oncology and respiratory-related biosimilars to South Africa region. Also, growing spending on pharmaceuticals research and rising healthcare infrastructure in emerging economies are anticipated to act as a catalyzing factor for the market demand during the forecast period. However, high cost associated with the drug development & distribution and complex process of drug development and approvals impede the growth of the market over the forecast period of 2022-2028.

The key regions considered for the global Oncology Biosimilars Market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America is the leading region across the world in terms of market share owing to rising R&D activities and increasing prevalence of cancer as well as presence of leading market players. Whereas, Asia Pacific is anticipated to exhibit a significant growth rate over the forecast period 2022-2028. Factors such as growing number of pharmaceutical contract manufacturers and rising healthcare spending in the region, would create lucrative growth prospects for the Oncology Biosimilars Market across the Asia Pacific region.

Major market players included in this report are:

Pfizer Inc. (U.S.)

GlaxoSmithKline plc (U.K.)

Novartis AG (Switzerland)

Mylan N.V. (U.S.)

Teva Pharmaceutical Industries Ltd.(Israel)

Sanofi (France)

F. Hoffmann-La Roche Ltd. (Switzerland)

Zydus Cadila (India)

Lupin (India)

Amneal Pharmaceuticals LLC. (U.S.)

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Indication

Breast Cancer

Lung Cancer

Colorectal Cancer

Cervical Cancer

Blood Cancer

Others

By Drug Class

Monoclonal Antibodies

Granulocyte Colony-Stimulating Factor

Others

By Route of Administration

Intravenous

Subcutaneous

Others

By End-Users

Hospitals

Specialty Clinics

Homecare

Others

By Distribution Channel

Hospital Pharmacy

Retail Pharmacy

Online Pharmacy

Others

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

ROE

Asia Pacific

China

India

Japan

Australia

South Korea

RoAPAC

Latin America

Brazil

Mexico

Rest of the World

Furthermore, years considered for the study are as follows:

Historical year - 2018, 2019, 2020

Base year - 2021

Forecast period - 2022 to 2028

Target Audience of the Global Oncology Biosimilars Market in Market Study:

Key Consulting Companies & Advisors

Large, medium-sized, and small enterprises

Venture capitalists

Value-Added Resellers (VARs)

Third-party knowledge providers

Investment bankers

Investors

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2028 (USD Million)
    • 1.2.1. Global Oncology Biosimilars Market, by Region, 2020-2028 (USD Million)
    • 1.2.2. Global Oncology Biosimilars Market, by Indication, 2020-2028 (USD Million)
    • 1.2.3. Global Oncology Biosimilars Market, by Drug Class, 2020-2028 (USD Million)
    • 1.2.4. Global Oncology Biosimilars Market, by Route of Administration, 2020-2028 (USD Million)
    • 1.2.5. Global Oncology Biosimilars Market, by End-Users, 2020-2028 (USD Million)
    • 1.2.6. Global Oncology Biosimilars Market, by Distribution Channel, 2020-2028 (USD Million)
    • 1.2.7.
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Oncology Biosimilars Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Scope of the Study
    • 2.2.2. Industry Evolution
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Oncology Biosimilars Market Dynamics

  • 3.1. Oncology Biosimilars Market Impact Analysis (2020-2028)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Growing prevalence of cancer worldwide.
      • 3.1.1.2. increasing demand for biosimilar drugs due to affordability.
      • 3.1.1.3. Recent partnerships and product launches from leading players.
    • 3.1.2. Market Challenges
      • 3.1.2.1. high cost associated with the drug development & distribution.
      • 3.1.2.2. Complex process of drug development and approvals.
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Growing spending on pharmaceuticals research.
      • 3.1.3.2. Rising healthcare infrastructure in emerging economies.

Chapter 4. Global Oncology Biosimilars Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
    • 4.1.6. Futuristic Approach to Porter's 5 Force Model (2018-2028)
  • 4.2. PEST Analysis
    • 4.2.1. Political
    • 4.2.2. Economical
    • 4.2.3. Social
    • 4.2.4. Technological
  • 4.3. Investment Adoption Model
  • 4.4. Analyst Recommendation & Conclusion
  • 4.5. Top investment opportunity
  • 4.6. Top winning strategies

Chapter 5. Risk Assessment: COVID-19 Impact

    • 5.1.1. Assessment of the overall impact of COVID-19 on the industry
    • 5.1.2. Pre COVID-19 and post COVID-19 Market scenario

Chapter 6. Global Oncology Biosimilars Market, by Indication

  • 6.1. Market Snapshot
  • 6.2. Global Oncology Biosimilars Market by Indication, Performance - Potential Analysis
  • 6.3. Global Oncology Biosimilars Market Estimates & Forecasts by Indication 2018-2028 (USD Million)
  • 6.4. Oncology Biosimilars Market, Sub Segment Analysis
    • 6.4.1. Breast Cancer
    • 6.4.2. Lung Cancer
    • 6.4.3. Colorectal Cancer
    • 6.4.4. Cervical Cancer
    • 6.4.5. Blood Cancer
    • 6.4.6. Others

Chapter 7. Global Oncology Biosimilars Market, by Drug Class

  • 7.1. Market Snapshot
  • 7.2. Global Oncology Biosimilars Market by Drug Class, Performance - Potential Analysis
  • 7.3. Global Oncology Biosimilars Market Estimates & Forecasts by Drug Class 2018-2028 (USD Million)
  • 7.4. Oncology Biosimilars Market, Sub Segment Analysis
    • 7.4.1. Monoclonal Antibodies
    • 7.4.2. Granulocyte Colony-Stimulating Factor
    • 7.4.3. Others

Chapter 8. Global Oncology Biosimilars Market, by Route of Administration

  • 8.1. Market Snapshot
  • 8.2. Global Oncology Biosimilars Market by Route of Administration, Performance - Potential Analysis
  • 8.3. Global Oncology Biosimilars Market Estimates & Forecasts by Route of Administration 2018-2028 (USD Million)
  • 8.4. Oncology Biosimilars Market, Sub Segment Analysis
    • 8.4.1. Intravenous
    • 8.4.2. Subcutaneous
    • 8.4.3. Others

Chapter 9. Global Oncology Biosimilars Market, by End-Users

  • 9.1. Market Snapshot
  • 9.2. Global Oncology Biosimilars Market by End-Users, Performance - Potential Analysis
  • 9.3. Global Oncology Biosimilars Market Estimates & Forecasts by End-Users 2018-2028 (USD Million)
  • 9.4. Oncology Biosimilars Market, Sub Segment Analysis
    • 9.4.1. Hospitals
    • 9.4.2. Specialty Clinics
    • 9.4.3. Homecare
    • 9.4.4. Others

Chapter 10. Global Oncology Biosimilars Market, by Distribution Channel

  • 10.1. Market Snapshot
  • 10.2. Global Oncology Biosimilars Market by Distribution Channel, Performance - Potential Analysis
  • 10.3. Global Oncology Biosimilars Market Estimates & Forecasts by Distribution Channel 2018-2028 (USD Million)
  • 10.4. Oncology Biosimilars Market, Sub Segment Analysis
    • 10.4.1. Hospital Pharmacy
    • 10.4.2. Retail Pharmacy
    • 10.4.3. Online Pharmacy
    • 10.4.4. Others

Chapter 11. Global Oncology Biosimilars Market, Regional Analysis

  • 11.1. Oncology Biosimilars Market, Regional Market Snapshot
  • 11.2. North America Oncology Biosimilars Market
    • 11.2.1. U.S. Oncology Biosimilars Market
      • 11.2.1.1. Indication estimates & forecasts, 2018-2028
      • 11.2.1.2. Drug Class estimates & forecasts, 2018-2028
      • 11.2.1.3. Route of Administration estimates & forecasts, 2018-2028
      • 11.2.1.4. End-Users estimates & forecasts, 2018-2028
      • 11.2.1.5. Distribution Channel estimates & forecasts, 2018-2028
    • 11.2.2. Canada Oncology Biosimilars Market
  • 11.3. Europe Oncology Biosimilars Market Snapshot
    • 11.3.1. U.K. Oncology Biosimilars Market
    • 11.3.2. Germany Oncology Biosimilars Market
    • 11.3.3. France Oncology Biosimilars Market
    • 11.3.4. Spain Oncology Biosimilars Market
    • 11.3.5. Italy Oncology Biosimilars Market
    • 11.3.6. Rest of Europe Oncology Biosimilars Market
  • 11.4. Asia-Pacific Oncology Biosimilars Market Snapshot
    • 11.4.1. China Oncology Biosimilars Market
    • 11.4.2. India Oncology Biosimilars Market
    • 11.4.3. Japan Oncology Biosimilars Market
    • 11.4.4. Australia Oncology Biosimilars Market
    • 11.4.5. South Korea Oncology Biosimilars Market
    • 11.4.6. Rest of Asia Pacific Oncology Biosimilars Market
  • 11.5. Latin America Oncology Biosimilars Market Snapshot
    • 11.5.1. Brazil Oncology Biosimilars Market
    • 11.5.2. Mexico Oncology Biosimilars Market
  • 11.6. Rest of The World Oncology Biosimilars Market

Chapter 12. Competitive Intelligence

  • 12.1. Top Market Strategies
  • 12.2. Company Profiles
    • 12.2.1. Pfizer Inc. (US)
      • 12.2.1.1. Key Information
      • 12.2.1.2. Overview
      • 12.2.1.3. Financial (Subject to Data Availability)
      • 12.2.1.4. Product Summary
      • 12.2.1.5. Recent Developments
    • 12.2.2. GlaxoSmithKline plc (U.K.)
    • 12.2.3. Novartis AG (Switzerland)
    • 12.2.4. Mylan N.V. (U.S.)
    • 12.2.5. Teva Pharmaceutical Industries Ltd. (Israel)
    • 12.2.6. Sanofi (France)
    • 12.2.7. F. Hoffmann-La Roche Ltd. (Switzerland)
    • 12.2.8. Zydus Cadila (India)
    • 12.2.9. Lupin (India)
    • 12.2.10. Amneal Pharmaceuticals LLC. (U.S.)

Chapter 13. Research Process

  • 13.1. Research Process
    • 13.1.1. Data Mining
    • 13.1.2. Analysis
    • 13.1.3. Market Estimation
    • 13.1.4. Validation
    • 13.1.5. Publishing
  • 13.2. Research Attributes
  • 13.3. Research Assumption

LIST OF TABLES

List of Tables

  • TABLE 1. Global Oncology Biosimilars Market, report scope
  • TABLE 2. Global Oncology Biosimilars Market estimates & forecasts by Region 2018-2028 (USD Million)
  • TABLE 3. Global Oncology Biosimilars Market estimates & forecasts by Indication 2018-2028 (USD Million)
  • TABLE 4. Global Oncology Biosimilars Market estimates & forecasts by Drug Class 2018-2028 (USD Million)
  • TABLE 5. Global Oncology Biosimilars Market estimates & forecasts by Route of Administration 2018-2028 (USD Million)
  • TABLE 6. Global Oncology Biosimilars Market estimates & forecasts by End-Users 2018-2028 (USD Million)
  • TABLE 7. Global Oncology Biosimilars Market estimates & forecasts by Distribution Channel 2018-2028 (USD Million)
  • TABLE 8. Global Oncology Biosimilars Market by segment, estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 9. Global Oncology Biosimilars Market by region, estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 10. Global Oncology Biosimilars Market by segment, estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 11. Global Oncology Biosimilars Market by region, estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 12. Global Oncology Biosimilars Market by segment, estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 13. Global Oncology Biosimilars Market by region, estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 14. Global Oncology Biosimilars Market by segment, estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 15. Global Oncology Biosimilars Market by region, estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 16. Global Oncology Biosimilars Market by segment, estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 17. Global Oncology Biosimilars Market by region, estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 18. U.S. Oncology Biosimilars Market estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 19. U.S. Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 20. U.S. Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 21. Canada Oncology Biosimilars Market estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 22. Canada Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 23. Canada Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 24. UK Oncology Biosimilars Market estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 25. UK Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 26. UK Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 27. Germany Oncology Biosimilars Market estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 28. Germany Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 29. Germany Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 30. RoE Oncology Biosimilars Market estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 31. RoE Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 32. RoE Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 33. China Oncology Biosimilars Market estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 34. China Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 35. China Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 36. India Oncology Biosimilars Market estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 37. India Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 38. India Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 39. Japan Oncology Biosimilars Market estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 40. Japan Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 41. Japan Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 42. RoAPAC Oncology Biosimilars Market estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 43. RoAPAC Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 44. RoAPAC Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 45. Brazil Oncology Biosimilars Market estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 46. Brazil Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 47. Brazil Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 48. Mexico Oncology Biosimilars Market estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 49. Mexico Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 50. Mexico Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 51. RoLA Oncology Biosimilars Market estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 52. RoLA Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 53. RoLA Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 54. Row Oncology Biosimilars Market estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 55. Row Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 56. Row Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 57. List of secondary sources, used in the study of global Oncology Biosimilars Market
  • TABLE 58. List of primary sources, used in the study of global Oncology Biosimilars Market
  • TABLE 59. Years considered for the study
  • TABLE 60. Exchange rates considered

LIST OF FIGURES

List of figures

  • FIG 1. Global Oncology Biosimilars Market, research methodology
  • FIG 2. Global Oncology Biosimilars Market, Market estimation techniques
  • FIG 3. Global Market size estimates & forecast methods
  • FIG 4. Global Oncology Biosimilars Market, key trends 2021
  • FIG 5. Global Oncology Biosimilars Market, growth prospects 2022-2028
  • FIG 6. Global Oncology Biosimilars Market, porters 5 force model
  • FIG 7. Global Oncology Biosimilars Market, pest analysis
  • FIG 8. Global Oncology Biosimilars Market, value chain analysis
  • FIG 9. Global Oncology Biosimilars Market by segment, 2018 & 2028 (USD Million)
  • FIG 10. Global Oncology Biosimilars Market by segment, 2018 & 2028 (USD Million)
  • FIG 11. Global Oncology Biosimilars Market by segment, 2018 & 2028 (USD Million)
  • FIG 12. Global Oncology Biosimilars Market by segment, 2018 & 2028 (USD Million)
  • FIG 13. Global Oncology Biosimilars Market by segment, 2018 & 2028 (USD Million)
  • FIG 14. Global Oncology Biosimilars Market, regional snapshot 2018 & 2028
  • FIG 15. North America Oncology Biosimilars Market 2018 & 2028 (USD Million)
  • FIG 16. Europe Oncology Biosimilars Market 2018 & 2028 (USD Million)
  • FIG 17. Asia pacific Market 2018 & 2028 (USD Million)
  • FIG 18. Latin America Oncology Biosimilars Market 2018 & 2028 (USD Million)
  • FIG 19. Global Oncology Biosimilars Market, company Market share analysis (2021)